CIK 0001907108
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
Lexeo Therapeutics, Inc.
Sign in to watch- Ticker
- LXEO
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 854012572
- Phone
- +1 212-547-9879
- Business address
- 345 PARK AVENUE SOUTH, FLOOR 6, NEW YORK, NY, 10010
- 4 Open-market sale Chief Technical Officer sold 2,115 shares at an average $8.94 ($18,913)
- 4 Open-market sale Chief Medical Officer sold 3,382 shares at an average $8.94 ($30,242)
- 4 Open-market sale Chief Executive Officer sold 13,133 shares at an average $8.94 ($117,436)
- 4 Grant or award Chief Executive Officer acquired 2,193 shares (grant or award)
- 4/A Open-market sale Chief Executive Officer sold 1,115 shares at $4.67 ($5,205)
- 4 Grant or award Chief Financial Officer acquired 45,000 shares (grant or award)
- 3 Insider Initial Statement of Ownership
- 4 Open-market sale Chief Technical Officer sold 2,848 shares at $4.67 ($13,294)
- 4 Open-market sale Chief Legal Officer sold 542 shares at $4.67 ($2,530)
- 4 Open-market sale Chief Medical Officer sold 608 shares at $4.67 ($2,838)
- 4 Open-market sale Chief Executive Officer sold 2,735 shares at $4.67 ($12,767)
- 4 Open-market sale Chief Development Officer sold 382 shares at $4.67 ($1,783)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Open-market sale Chief Executive Officer sold 1,074 shares at $2.77 ($2,979)
Page 3 of 7 · 121 filings